Therapeutic area
Ophthalmology
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
10
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
62
Industry-sponsored
Recruiting Phase 3
44
Industry-sponsored
Recruiting Phase 4 (post-approval)
5
Industry-sponsored
Recent approvals
- Lytenava (Bevacizumab-Vikg) · Outlook Therapeutics, Inc. NovelJul 24, 2026
To treat patients with neovascular (wet) age-related macular degeneration
- Differin Epiduo Acne Gel (Adapalene and Benzoyl Peroxide) (Adapalene, Benzoyl Peroxide, Adapalene, Benzoyl Peroxide) · Galderma Labs Lp May 22, 2026
- Vizz (Aceclidine Hydrochloride) · Lenz Therap NovelJul 31, 2025
To treat presbyopia
- Tryptyr (Acoltremon) · Alcon Labs INC NovelMay 28, 2025
To treat the signs and symptoms of dry eye disease
- Attruby (Acoramidis Hydrochloride) · Bridgebio Pharma NovelOrphanNov 22, 2024
To treat cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis
- Wainua (Autoinjector) (Eplontersen Sodium) · Astrazeneca Ab NovelOrphanDec 21, 2023
To treat polyneuropathy of hereditary transthyretin-mediated amyloidosis
- Cabtreo (Adapalene, Benzoyl Peroxide, Clindamycin Phosphate) · Bausch Oct 20, 2023
- Sohonos (Palovarotene) · Ipsen NovelPriority reviewOrphanAug 16, 2023
To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva
- Izervay (Avacincaptad Pegol Sodium) · Astellas NovelBreakthrough therapyPriority reviewAug 4, 2023
To treat geographic atrophy secondary to age-related macular degeneration
- Miebo (Perfluorohexyloctane) · Bausch and Lomb INC NovelMay 18, 2023
To treat signs and symptoms of dry eye disease
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- TelitaciceptRC18, RC18-LPhase 38 trials
RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease
- siRNAADX-038, ADX-324Phase 37 trials
ADARx Pharmaceuticals, Inc. · Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1
- MHB018APhase 36 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Thyroid Eye Disease (TED), Thyroid Eye Disease, TED, Thyroid Associated Ophthalmopathies
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- CemdisiranALN-CC5Phase 35 trials
Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)
- NPI-001N-Acetylcysteine AmidePhase 35 trials
Nacuity Pharmaceuticals, Inc. · Retinitis Pigmentosa (RP), Usher Syndrome, Alzheimer´s Disease
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- ALXN2220Phase 34 trials
AstraZeneca · Transthyretin Amyloid Cardiomyopathy (ATTR-CM), Transthyretin Amyloid Cardiomyopathy, Amyloid Transthyretin Cardiomyopathy
- EYP-1901Phase 34 trials
EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
- OLN324Phase 34 trials
Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration
- PRL3-ZUMABPhase 34 trials
Intra-IMMUSG Pte Ltd · Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers
- ALK-001C20-D3-Retinyl Acetate, C20 Deuterated vitamin APhase 33 trials
Alkeus Pharmaceuticals, Inc. · Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy
- Bimatoprost Implant SystemPhase 33 trials
SpyGlass Pharma, Inc. · Cataract, Glaucoma, Ocular Hypertension
- NNC6019-0001Phase 33 trials
Novo Nordisk · Transthyretin Amyloid Cardiomyopathy (ATTR CM)
- OTX-TKIaxitinib implantPhase 33 trials
Ocular Therapeutix, Inc. · Neovascular Age-related Macular Degeneration, Neovascular Age-Related Macular Degeneration, Neovascular Age-Related Macular Degeneration (nAMD)
Largest recruiting Phase 3 trials
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705607 · 1,104 participants (planned) · Start Sep 25, 2026 · Primary completion Nov 30, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 31 sites in all
- Extension Study for the Port Delivery System With Ranibizumab (Portal)Pivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03683251 · 1,000 participants (planned) · Start Sep 20, 2018 · Primary completion Dec 31, 2029
Drug: PDS Implant with Ranibizumab 100 mg/mL · For: Neovascular Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Bakersfield, California; Beverly Hills, California · 165 sites in all
- A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyPivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT06541704 · 975 participants (planned) · Start Oct 30, 2024 · Primary completion Jul 31, 2028
Drug: Pozelimab; Cemdisiran and 1 more · For: Age-related Macular Degeneration (AMD); Geographic Atrophy (GA)
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 233 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07496567 · 960 participants (planned) · Start Apr 15, 2026 · Primary completion Jul 31, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Encino, California · 121 sites in all
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)Pivotal-lookingRecruiting
EyeBiotech Ltd.Industry
NCT07440225 · 960 participants (planned) · Start Mar 27, 2026 · Primary completion Jun 30, 2028
Drug: Tiespectus; Aflibercept · For: Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization and 1 more
Sites: Scottsdale, Arizona; Fayetteville, Arkansas; Springdale, Arkansas · 148 sites in all
- A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07705555 · 960 participants (planned) · Start Aug 27, 2026 · Primary completion Oct 31, 2028
Drug: MK-8748; Aflibercept · For: Diabetic Retinopathy; Macular Edema
Sites: Gilbert, Arizona; Glendale, California; Sacramento, California · 45 sites in all
- A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTOPivotal-lookingRecruiting
Kodiak Sciences IncIndustry
NCT07734844 · 910 participants (planned) · Start Aug 3, 2026 · Primary completion Aug 31, 2028
Drug: Tabirafusp tedromer; Aflibercept (2.0 mg) · For: Diabetic Macular Edema (DME)
Sites: Scottsdale, Arizona; Bakersfield, California; Glendale, California · 52 sites in all
Ocular Therapeutix, Inc.Industry
NCT07516132 · 850 participants (planned) · Start Apr 27, 2026 · Primary completion Aug 1, 2030
Drug: OTX-TKI · For: Neovascular Age-Related Macular Degeneration (nAMD)
Sites: Bakersfield, California; Santa Barbara, California; Waterford, Connecticut · 8 sites in all
- A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)Pivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT06747949 · 844 participants (planned) · Start Feb 25, 2025 · Primary completion Dec 11, 2029
Drug: Dazodalibep · For: Sjögren's Syndrome
Sites: Avondale, Arizona; Flagstaff, Arizona; Gilbert, Arizona · 174 sites in all
- Phase III Study of OT202 in Treating Moderate to Severe Dry EyePivotal-lookingRecruiting
Ocumension Therapeutics (Suzhou) Co., LtdIndustry
NCT07740564 · 842 participants (planned) · Start Aug 25, 2026 · Primary completion Jan 2029
Drug: OT202 conc 1%; Placebo · For: Dry Eye
Sites: Bengbu, China; Hefei, China; Beijing, China · 49 sites in all
More: Ophthalmology news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.